EGFR Uncommon Mutations, Including G719X and S768I

Explore clinical trials studying EGFR Uncommon Mutations, Including G719X and S768I. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

EGFR Uncommon Mutations, Including G719X and S768I trial results

Active, Not Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073

Conditions: Advanced Non-Small Cell Lung Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +13 more
Locations: ArriVent Investigative Site Prescott, Arizona, United States

ArriVent Investigative Site Sacramento, California, United States

ArriVent Investigative Site Whittier, California, United States

ArriVent Investigative Site Celebration, Florida, United States

View all 42 locations

View Trial Details

EGFR Uncommon Mutations, Including G719X and S768I

EGFR Uncommon Mutations, Including G719X and S768I trial results

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Related conditions